Open AccessTherapeutic Analysis of Fuzi Lizhong Wan with Trimebutine in the Treatment of Diarrhea Type Irritable Bowel Syndrome
Author(s) -
Yu Shan Chang,
Quanwei Di,
Gaixian Di
Publication year - 2020
Publication title -
journal of clinical and nursing research
Language(s) - English
Resource type - Journals
eISSN - 2208-3693
pISSN - 2208-3685
DOI - 10.26689/jcnr.v4i4.1337
Subject(s) - medicine , irritable bowel syndrome , diarrhea , gastroenterology , clinical efficacy
Objective: To evaluate the clinical efficacy of Fuzi Lizhong Wan and trimebutine in the treatment of diarrhea irritable bowel syndrome. Methods: A total of 90 patients with diarrhea irritable bowel syndrome were divided into control group
(n=45) and treatment group (n=45) using the random number table method. Patients in the control group were po administered with trimebutine 0.2 g, three time daily for 4 weeks. Patients in the treatment group were po administered with Fuzi Lizhong Wan 9 g, three time daily for 4 weeks on the basis of the control group. The clinical efficacy and the TCM symptom scores were evaluated after treatment. The serological indicators in two groups were compared before and after treatment. Results: After treatment, the clinical efficacy and the TCM symptom scores in treatment group were significantly lower than that in control group(P<0.05).The levels of serological indicators in both groups improved significantly, and those in the treatment group were better than the control group(P<0.05). Conclusion: Combined therapy of Fuzi Lizhong Wan and trimebutine in the treatment of diarrhea type irritable bowel syndrome has a significant effect, which can relieve clinical symptom, and reduce visceral sensitivity, and improve levels of inflammatory and quality of life. So it is suggested to be applied.